Spondyloarthritis & psoriatic arthritis
Rheumatologist and patient perspectives on axial spondyloarthritis management and treatment satisfaction in Europe
An erratum to this article was published (Semin Arthritis Rheum, Apr 2026 ↗)
Authors' conclusion
Patients and their rheumatologists were moderately aligned on their perception of disease severity and treatment satisfaction but differed in their expectations regarding treatment target.
Study context
- Population
- Adult patients with axial spondyloarthritis (axSpA) and their rheumatologists in France, Germany, Italy, Spain and the UK, June 2023–June 2024538 completed patient survey
- Participants
- 2,165 patients
- Outcome
- axSpA characteristics and management experiences
- Follow-up
- At the time of the survey
Methodological detailssurvey, real-world, multinational (France, Germany, Italy, Spain, UK), matched rheumatologist- and patient-reported responses
- Survey
- Real-world
- Multinational (France, Germany, Italy, Spain, UK)
- Matched rheumatologist- and patient-reported responses
Main finding
As reported in the abstract
- Ongoing morning stiffness
- 35 %
- Ongoing inflammatory back, hip, or buttock pain
- 25 %
- Ongoing fatigue
- 25 %
- Received disease-modifying advanced therapy
- 77 %
- Patient–rheumatologist agreement on disease severity (weighted agreement)
- 86 %
- Patient–rheumatologist agreement on disease severity (κ)
- 0.515
- Most common rheumatologist target: low disease activity
- 76 %
- Most common patient target: alleviate pain
- 61 %
Observational data: associations, not effects.
Original publication
Rheumatologist and patient perspectives on axial spondyloarthritis management and treatment satisfaction in Europe. Semin Arthritis Rheum. Published 22 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →